Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6-grass pollen polymerized extract immunotherapy trial in grass pollen allergic rhinitis/rhinoconjunctivitis
2026-526100-73-00Phase 3Authorised
- Sponsor
- Inmunotek
- Start
- Oct 2026
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of 6-grass pollen polymerized extract in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and asthma (3 arms), sponsored by Inmunotek. Primary endpoint: Mean daily Rhinitis/Rhinoconjunctivitis Combined Symptom and Medication Score during peak grass pollen season. Planned start Oct 2026; status: authorised.
02
Drugs
6-grass pollen polymerized extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on 2026-526100-73-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526100-73-00.